<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pemigatinib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pemigatinib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pemigatinib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="127980" href="/d/html/127980.html" rel="external">see "Pemigatinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54356832"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Pemazyre</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56591830"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Pemazyre</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F54331420"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Fibroblast Growth Factor Receptor (FGFR) Inhibitor;</li>
<li>
                        Antineoplastic Agent, Tyrosine Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F54340705"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="024557a7-38fa-427e-93f4-7c351f1600de">Cholangiocarcinoma, unresectable, locally advanced or metastatic, with susceptible fibroblast growth factor receptor 2 genetic alteration</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cholangiocarcinoma, unresectable, locally advanced or metastatic, with susceptible fibroblast growth factor receptor 2 genetic alteration: Oral: </b>13.5 mg once daily on days 1 to 14 of a 21-day cycle; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32203698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32203698'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3410988a-2200-4efb-a20e-8142c5b66ff0">Myeloid/lymphoid neoplasms, relapsed/refractory, with fibroblast growth factor receptor 1 rearrangement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myeloid/lymphoid neoplasms, relapsed/refractory, with fibroblast growth factor receptor 1 rearrangement:</b>
<b>Oral:</b> 13.5 mg once daily (on a continuous basis); continue until disease progression or unacceptable toxicity.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed or vomited doses:</i> If a dose is missed by ≥4 hours or if vomiting occurs, resume pemigatinib with the next scheduled dose the following day.</p></div>
<div class="block dora drugH1Div" id="F54340707"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> GFR estimated by the Modification of Diet in Renal Disease equation.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR 30 to 89 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>: Reduce dose to 9 mg once daily (either intermittent or continuous, depending on the indication).</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease receiving intermittent hemodialysis (eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>): No dosage adjustment is recommended.</p></div>
<div class="block doha drugH1Div" id="F54340708"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild (total bilirubin &gt;1 to 1.5 times ULN or AST &gt; ULN) or moderate (total bilirubin &gt;1.5 to 3 times ULN with any AST) impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (totally bilirubin &gt;3 times ULN with any AST): Reduce dose to 9 mg once daily (either intermittent or continuous, depending on the indication).</p></div>
<div class="block dot drugH1Div" id="F54340709"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Pemigatinib Dose Reduction Levels </b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:center;">
<b>Dose Levels </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:center;">
<b>Cholangiocarcinoma</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:center;">
<b>Myeloid/lymphoid neoplasms</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup> Permanently discontinue pemigatinib if unable to tolerate 4.5 mg once daily for 14 days of a 21-day cycle.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">Usual initial dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">13.5 mg once daily on days 1 to 14 of a 21-day cycle</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">13.5 mg once daily (on a continuous basis)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">First dose reduction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">9 mg once daily on days 1 to 14 of a 21-day cycle</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">9 mg once daily (continuously)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">Second dose reduction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">4.5 mg once daily on days 1 to 14 of a 21-day cycle<sup>a</sup></p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">4.5 mg once daily (continuously)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:center;">Third dose reduction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">Permanently discontinue pemigatinib.</p></td>
<td align="left">
<p style="text-indent:0em;text-align:center;">4.5 mg once daily on days 1 to 14 of a 21-day cycle<sup>a</sup></p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Pemigatinib Recommended Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">Adverse reaction</p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">Severity</p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">Pemigatinib dose modification</p></th></tr></thead>
<tbody>
<tr>
<td align="left" rowspan="4">
<p style="text-indent:0em;text-align:left;">Hyperphosphatemia</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Serum phosphate level &gt;5.5 to ≤7 mg/dL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Monitor for hyperphosphatemia and initiate a low-phosphate diet. Continue pemigatinib at current dose.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Serum phosphate level &gt;7 to ≤10 mg/dL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Initiate phosphate-lowering therapy; monitor serum phosphate weekly. If phosphate level is not &lt;7 mg/dL within 2 weeks of initiating phosphate binders, withhold pemigatinib. Resume pemigatinib at the same dose when phosphate level is &lt;7 mg/dL (for first occurrence); resume pemigatinib at a lower dose level for subsequent occurrences of hyperphosphatemia.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Serum phosphate level &gt;10 mg/dL</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Initiate phosphate-lowering therapy; monitor serum phosphate weekly. If phosphate level is not ≤10 mg/dL within 1 week of initiating phosphate binders, withhold pemigatinib. Resume pemigatinib at the next lower dose level when phosphate level is &lt;7 mg/dL.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Recurrence of serum phosphate level &gt;10 mg/dL (after 2 dose reductions)</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue pemigatinib.</p></td></tr>
<tr>
<td align="left" rowspan="3">
<p style="text-indent:0em;text-align:left;">Ocular toxicity</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Dry eye symptoms</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Administer dry eye prophylaxis/treatment (with ocular demulcents) as needed.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Retinal pigment epithelial detachment: Asymptomatic and stable</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If retinal pigment epithelial detachment is asymptomatic and stable on serial ophthalmological examination, continue pemigatinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Retinal pigment epithelial detachment: Symptomatic or worsening</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">If retinal pigment epithelial detachment is symptomatic or worsening on serial ophthalmological examination, withhold pemigatinib. If retinal pigment epithelial detachment is asymptomatic and improved on subsequent examination, resume pemigatinib at a lower dose. If symptoms persist or examination does not improve, consider permanent discontinuation of pemigatinib (depending on clinical status).</p></td></tr>
<tr>
<td align="left" rowspan="2">
<p style="text-indent:0em;text-align:left;">Other adverse reactions</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 3</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Withhold pemigatinib therapy until improvement to grade 1 or baseline. If toxicity resolves within 2 weeks, resume pemigatinib at the next lower dose. If toxicity does not resolve within 2 weeks, or for recurrent grade 3 toxicity (after 2 dose reductions), permanently discontinue pemigatinib.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Permanently discontinue pemigatinib.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F54340706"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F54442933"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Hyperphosphatemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib can cause <b>hyperphosphatemia</b>, leading to soft tissue mineralization, <b>cutaneous calcification</b>, <b>calcinosis</b>, and non-uremic calciphylaxis. In clinical trials, 33% of patients required phosphate-binder therapy; a low-phosphate diet may also have been necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32203698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32203698'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; related to the pharmacologic action (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32203698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32203698'])">Ref</a></span>). Pemigatinib inhibits fibroblast growth factor receptor, resulting in increased serum phosphate concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; median time to onset is 8 days (range: 1 to 169 days)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dry eye syndrome</b> (some necessitating treatment with ophthalmic lubricant) has commonly occurred. <b>Retinal pigment epithelial detachment</b> (RPED) has occurred as well as other ophthalmic disorders including <b>increased lacrimation</b>, <b>keratitis</b>, <b>maculopathy, meibomianitis,</b>
<b>punctate keratitis, and retinopathy</b>. Overall, ocular toxicities are common, although grade 3 and 4 ocular toxicities rarely occur.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Pemigatinib causes subretinal fluid accumulation potentially due to fibroblast growth factor receptor inhibition and the consequential inhibition of the mitogen-activating protein kinase pathway, resulting in dysregulation of the outer retinal barrier or functions of the retinal pigment epithelium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32203698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32203698'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Delayed; median time to first onset of RPED was 56 days in clinical trials; resolution or improvement to grade 1 toxicity occurred in 76% of patients after dose adjustments.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F54341082"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (18% to 21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (49% to 59%), changes in nails (43% to 62%; including nail bed changes, nail discoloration, onychoclasis, onycholysis, onychomadesis, onychomycosis, paronychia), palmar-plantar erythrodysesthesia (15% to 18%), skin rash (35%; including acneiform eruption, dermatitis, exfoliation of skin, and lichen planus), xeroderma (20% to 24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin (34%), decreased serum calcium (17% to 26%), decreased serum glucose (11%), decreased serum potassium (24% to 26%), decreased serum sodium (39% to 41%), dehydration (15%), hyperphosphatemia (60% to 93%), hypophosphatemia (23%), increased serum calcium (26% to 43%), increased serum glucose (33% to 36%), increased serum potassium (12%), increased uric acid (18% to 30%), weight loss (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (23% to 35%), constipation (32% to 35%), decreased appetite (24% to 33%), diarrhea (47% to 50%; grades 3/4: 3%), dysgeusia (40%), dyspepsia (24%), nausea (21% to 40%; grades 3/4: 2%), stomatitis (35% to 53%; grades 3/4: 5% to 15%), vomiting (27%; grades 3/4: 1%), xerostomia (32% to 34%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia 35%; grades 3/4: 18%), decreased neutrophils (45%; grades 3/4: 12%), decreased platelet count (28% to 29%; grades 3/4: 3% to 15%), increased INR (grade 1/2: ≤16%), leukocytosis (27%; grades 3/4: &lt;1%), leukopenia (18% to 65%; grades 3/4: 1% to 15%), lymphocytopenia (36% to 65%; grades 3/4: 8% to 16%), prolonged prothrombin time (grades 1/2: ≤16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (43% to 50%), increased serum alkaline phosphatase (41% to 62%), increased serum aspartate aminotransferase (43% to 47%), increased serum bilirubin (21% to 26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (21%), fatigue (42% to 44%; including asthenia), headache (16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (25%), back pain (20% to 24%), limb pain (19% to 26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (21%), dry eye syndrome (31% to 50%; including increased lacrimation, keratitis, meibomianitis, punctate keratitis), misdirected growth of eyelashes (18%), retinal pigment epithelium detachment (11% to 26%; including maculopathy and retinopathy)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (41% to 44%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (29%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Neuromuscular &amp; skeletal: Bone fracture (2%; pathological fracture: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Heart failure, hypotension, prolonged QT interval on ECG, syncope, vascular calcification (non-uremic calciphylaxis)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cutaneous calcification</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Calcinosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholangitis (including infective), intestinal obstruction</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pleural effusion</p></div>
<div class="block coi drugH1Div" id="F54331386"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to pemigatinib or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F54340659"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal function: Elevations in serum creatinine (mean increase of 0.2 mg/dL) occurred during the initial 3-week pemigatinib cycle, reaching steady state by day 8 and decreasing during the 7 days off therapy. If persistent serum creatinine elevations are observed, consider alternative markers for renal function evaluation.</p>
<p style="text-indent:-4em;margin-left:4em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-4em;margin-left:6em;">• Fibroblast growth factor receptor alteration: Pemigatinib is approved for the treatment of locally advanced or metastatic cholangiocarcinoma in patients based on the presence of a fibroblast growth factor receptor (FGFR) 2 fusion or rearrangement and for the treatment of relapsed/refractory myeloid/lymphoid neoplasms in patients with FGFR 1 rearrangement. Information on available approved tests may be found at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2FCompanionDiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IPc%2BkYYsON95PtA1EteUbfjUoJYJ%2BuveJw2PtFUTXMkK&amp;TOPIC_ID=127947" target="_blank">http://www.fda.gov/CompanionDiagnostics</a>.</p></div>
<div class="block foc drugH1Div" id="F54356833"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pemazyre: 4.5 mg, 9 mg, 13.5 mg</p></div>
<div class="block geq drugH1Div" id="F54356831"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F54407925"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Pemazyre Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4.5 mg (per each): $1,545.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">9 mg (per each): $1,545.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">13.5 mg (per each): $1,545.86</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56591831"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Pemazyre: 4.5 mg, 9 mg, 13.5 mg</p></div>
<div class="block adm drugH1Div" id="F54340710"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with or without food at approximately the same time each day. Swallow tablets whole; do not crush, chew, split, or dissolve tablets.</p></div>
<div class="block hazard drugH1Div" id="F54340661"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Pemigatinib may cause reproductive toxicity and teratogenicity.</p>
<p style="text-indent:-2em;margin-left:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F54331385"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cholangiocarcinoma, unresectable, locally advanced or metastatic:</b> Treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement (as detected by an approved test).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Myeloid/lymphoid neoplasms, relapsed/refractory:</b> Treatment of relapsed or refractory myeloid/lymphoid neoplasms in adults with fibroblast growth factor receptor 1 (FGFR1) rearrangement.</p></div>
<div class="block mst drugH1Div" id="F54340654"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pemigatinib may be confused with brigatinib, erdafitinib, pazopanib, pegaptanib, pembrolizumab, pemetrexed, pexidartinib, ponatinib.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F54367794"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F54367791"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Pemigatinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Pemigatinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Pemigatinib. Management: If combined use cannot be avoided, reduce the pemigatinib dose from 13.5 mg daily to 9 mg daily, or from 9 mg daily to 4.5 mg daily. Resume prior pemigatinib dose after stopping the moderate inhibitor once 3 half-lives of the inhibitor has passed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Pemigatinib. Management: If combined use cannot be avoided, reduce the pemigatinib dose from 13.5 mg daily to 9 mg daily, or from 9 mg daily to 4.5 mg daily. Resume prior pemigatinib dose after stopping the strong inhibitor once 3 half-lives of the inhibitor has passed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: Serum Phosphate Level-Altering Agents may diminish the therapeutic effect of Erdafitinib.  Management: Avoid coadministration of serum phosphate level-altering agents with erdafitinib before initial dose increase period based on serum phosphate levels (Days 14 to 21).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54340657"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who could become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who could become pregnant should use effective contraception during pemigatinib therapy and for 1 week after the last dose. Patients with partners who could become pregnant should use effective contraception during therapy and for 1 week after the last pemigatinib dose.</p></div>
<div class="block pri drugH1Div" id="F54340656"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to pemigatinib may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F54340658"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if pemigatinib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during treatment and for 1 week after the last pemigatinib dose.</p></div>
<div class="block mop drugH1Div" id="F54340712"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Assess for susceptible fibroblast growth factor receptor (FGFR) 2 genetic alteration in cholangiocarcinoma or for FGFR 1 rearrangement in myeloid/lymphoid neoplasms; serum phosphate level as clinically necessary (monitor weekly if hyperphosphatemia develops). Evaluate pregnancy status prior to use in patients who could become pregnant. Ophthalmological exams (including optical coherence tomography) at baseline and then every 2 months for the first 6 months of pemigatinib therapy, then every 3 months thereafter, and as clinically necessary (if retinal pigment epithelial detachment occurs, follow up evaluations every 3 weeks until resolved or until pemigatinib is discontinued). Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F54340663"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pemigatinib is a fibroblast growth factor receptor (FGFR) kinase inhibitor that binds to and inhibits FGFR1, FGFR2, and FGFR3 enzyme activity. FGFR phosphorylation inhibition results in decreased FGFR-related signaling and decreased cell viability in cell lines expressing FGFR genetic alterations, leading to decreased proliferation and survival of malignant cells.</p></div>
<div class="block phk drugH1Div" id="F54340664"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~235 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~91%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic via CYP3A4.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 15.4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~1 hour (range: 0.5 to 6 hours).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces: 82.4% (1.4% as unchanged drug); urine: 12.6% (1% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 10.6 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F55578511"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The geometric mean pemigatinib AUC<sub>0-inf</sub> increased by 59% in patients with severe renal impairment (eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>) compared to subjects with normal renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: The geometric mean pemigatinib AUC<sub>0-inf</sub> increased by 136% in subjects with severe hepatic impairment (total bilirubin &gt;3 × ULN) compared to subjects with normal hepatic function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56713674"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Pemazyre</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Pemazyre</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Pemazyre</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Pemazyre</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Pemazyre</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Pemazyre</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Pemazyre</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Pemazyre</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Pemazyre</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Pemazyre</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Pemazyre</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Pemazyre</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Pemazyre</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32203698">
<a name="32203698"></a>Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. <i>Lancet Oncol</i>. 2020;21(5):671-684. doi:10.1016/S1470-2045(20)30109-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemigatinib-drug-information/abstract-text/32203698/pubmed" id="32203698" target="_blank">32203698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pemigatinib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-pemazyre.1">
<a name="pemazyre.1"></a>Pemazyre (pemigatinib) [prescribing information]. Wilmington, DE: Incyte Corporation; June 2023.</div>
</li>
<li>
<div class="reference">
                  Pemazyre (pemigatinib) [product monograph]. Oakville, Ontario, Canada: Innomar Strategies; September 2021.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed April 20, 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 127947 Version 62.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
